LSV Asset Management Has $65.84 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

LSV Asset Management raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1,651.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,774,707 shares of the biotechnology company's stock after buying an additional 2,616,278 shares during the period. LSV Asset Management owned approximately 0.95% of Exelixis worth $65,844,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new position in shares of Exelixis in the 1st quarter worth approximately $1,281,000. Nordea Investment Management AB grew its stake in shares of Exelixis by 17.3% in the 1st quarter. Nordea Investment Management AB now owns 202,292 shares of the biotechnology company's stock worth $4,835,000 after purchasing an additional 29,784 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Exelixis by 6.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 60,746 shares of the biotechnology company's stock worth $1,442,000 after purchasing an additional 3,510 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Exelixis by 3.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,771 shares of the biotechnology company's stock worth $778,000 after purchasing an additional 1,301 shares during the last quarter. Finally, Smith Group Asset Management LLC acquired a new position in shares of Exelixis in the 1st quarter worth approximately $228,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Wall Street Analyst Weigh In

EXEL has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Exelixis in a research note on Friday, May 3rd. StockNews.com upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a report on Saturday. TheStreet upgraded shares of Exelixis from a "c+" rating to a "b-" rating in a report on Monday, March 18th. Barclays cut shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $25.00 target price for the company. in a report on Thursday, April 11th. Finally, Stephens initiated coverage on shares of Exelixis in a report on Tuesday, May 14th. They issued an "equal weight" rating and a $23.00 target price for the company. Seven research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $26.13.

Exelixis Trading Down 0.7 %

NASDAQ EXEL traded down $0.15 during trading on Friday, reaching $22.40. The company's stock had a trading volume of 1,189,764 shares, compared to its average volume of 1,464,264. The stock has a market capitalization of $6.79 billion, a PE ratio of 35.00, a PEG ratio of 0.55 and a beta of 0.54. The business has a 50-day moving average price of $21.69 and a 200-day moving average price of $22.24. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $24.34.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.16). Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The business had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. During the same quarter last year, the firm earned $0.12 earnings per share. Exelixis's revenue was up 4.0% compared to the same quarter last year. As a group, analysts expect that Exelixis, Inc. will post 1.15 earnings per share for the current year.

Insiders Place Their Bets

In other Exelixis news, Director Jack L. Wyszomierski sold 8,287 shares of the business's stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the transaction, the director now owns 349,499 shares of the company's stock, valued at approximately $7,688,978. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Exelixis news, Director George Poste sold 11,686 shares of the business's stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $20.96, for a total transaction of $244,938.56. Following the completion of the transaction, the director now owns 213,907 shares of the company's stock, valued at approximately $4,483,490.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack L. Wyszomierski sold 8,287 shares of the company's stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total transaction of $182,314.00. Following the transaction, the director now directly owns 349,499 shares of the company's stock, valued at approximately $7,688,978. The disclosure for this sale can be found here. Insiders sold a total of 30,896 shares of company stock valued at $660,677 in the last quarter. Insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.